Cantor Fitzgerald Believes Supernus Pharmaceuticals (NASDAQ: SUPN) Still Has Room to Grow

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Supernus Pharmaceuticals (NASDAQ: SUPN), with a price target of $55. The company’s shares opened today at $47.95, close to its 52-week high of $50.30.

Tanner noted:

“Oxtellar XR monotherapy indication looks like an attractive incremental opportunity to us. In April, the FDA accepted the company’s efficacy supplement in support of Oxtellar XR indication expansion to include monotherapy treatment of partial seizures of epilepsy. The current indication is for adjunctive treatment. The CEO noted that Oxtellar XR has been competing in a market of approximately 2-2.5 million oxcarbazepine Rxs (half of the total oxcarbazepine Rxs owing to the fact that the balance is prescribed by psychiatrists). The CEO noted that 56% of epilepsy drug Rxs, 13.6 million, are for monotherapy. SUPN expects an FDA decision by YE18.”

According to TipRanks.com, Tanner is a 4-star analyst with an average return of 7.6% and a 50.6% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Intra-Cellular Therapies, and Aquinox Pharmaceuticals.

Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $50.50.

See today’s analyst top recommended stocks >>

Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $26.35 million. In comparison, last year the company had a net profit of $10.3 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi, which treats patients with epilepsy.